Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135941 · ClinicalTrials.gov registry record · Phase 3
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 582
- Enrollment target
NCT00135941 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 582 participants.
The verdict
NCT00135941, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 582 participants
- Enrollment target
Study Summary
The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.
Interventions
- DRUG insulin glargine
- DRUG insulin glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135941
The ClinicalTrials.gov registry entry for NCT00135941 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT00135941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135941 about?
NCT00135941 is a clinical study titled "Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)". The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.
What is the current status of trial NCT00135941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 582 participants. The study started on 2005-08. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00135941?
The interventions under investigation include: insulin glargine (DRUG), insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT00135941?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.